Full Press Release Details
LOS ANGELES--(BUSINESS WIRE)--Neil Bhowmick, President and CSO of Kairos Pharma, presents on lead candidate ENV-105 and its interim efficacy results at Cancer R&D 2026.
KAPA Positive Sentiment
Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
Key Takeaway: Neil Bhowmick, Kairos Pharma’s President and CSO, presented interim efficacy results for lead candidate ENV-105 at the United Scientific Group’s 11th International Conference on Cancer Research & Drug Development. The presentation focused on the drug's performance in cancer research. This update provides early insight into the potential of ENV-105.
Market Sentiment Analysis
POSITIVE FACTORS
- Kairos Pharma presented interim efficacy data for ENV-105.
- Company leadership engaged at a major international conference.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~5 mo
High dilution risk
Lead asset
Carotuximab
Phase 1 · Non Small Cell Lung Cancer
Frequently Asked Questions
What is ENV-105?
ENV-105 is Kairos Pharma's lead candidate in cancer research.
Who presented at the conference?
Neil Bhowmick, President and CSO of Kairos Pharma, presented.
What were the results presented?
The presentation included interim efficacy results for ENV-105.
What conference did Kairos Pharma attend?
They attended the United Scientific Group's 11th International Conference.